Concepedia

An FDA oncology analysis of immune activating products and first-in-human dose selection

Haleh Saber, Ramadevi Gudi, Michael L. Manning, Emily Wearne, John K. Leighton

Regulatory Toxicology and Pharmacology · 2016 · 52 citations · 8 references

DOI

Concepts

References

8

Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412

Ganesh Suntharalingam, Meghan Perry, Stephen Ward et al. · New England Journal of Medicine · 2006 · 2.1K citations

, , +16

Cancer Immunotherapy

Jennifer Couzin-Frankel · Science · 2013 · 2K citations

, , +13

Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

Fubin Li, Jeffrey V. Ravetch · Science · 2011 · 335 citations

, , +17

“Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics

Richard Stebbings, Lucy Findlay, Cherry Edwards et al. · The Journal of Immunology · 2007 · 314 citations · Full text

, , +16

An FDA oncology analysis of antibody-drug conjugates

Haleh Saber, John K. Leighton · Regulatory Toxicology and Pharmacology · 2015 · 172 citations

, , +14